labetalol has been researched along with Brain Vascular Disorders in 6 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous labetalol is commonly used in the management of hypertensive emergencies or urgencies as well as postoperative hypertension." | 7.67 | The safety of cumulative doses of labetalol in perioperative hypertension. ( Cosentino, F; Little, JR; Orlowski, JP; Shiesley, D; Vidt, DG, 1989) |
| "Intravenous labetalol is commonly used in the management of hypertensive emergencies or urgencies as well as postoperative hypertension." | 3.67 | The safety of cumulative doses of labetalol in perioperative hypertension. ( Cosentino, F; Little, JR; Orlowski, JP; Shiesley, D; Vidt, DG, 1989) |
| " At dosage levels similar to arotinolol, both pindolol and labetalol were less effective in preventing cerebral lesions despite lower blood pressure." | 1.28 | Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP. ( Hara, Y; Maniwa, T; Miyagishi, A; Noguchi, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ram, CV | 2 |
| Patel, RV | 1 |
| Kertland, HR | 1 |
| Jahns, BE | 1 |
| Zarowitz, BJ | 1 |
| Mlynarek, ME | 1 |
| Fagan, SC | 1 |
| Trejo Gabriel y Galán, JM | 1 |
| Miyagishi, A | 1 |
| Maniwa, T | 1 |
| Noguchi, T | 1 |
| Hara, Y | 1 |
| Cosentino, F | 1 |
| Vidt, DG | 1 |
| Orlowski, JP | 1 |
| Shiesley, D | 1 |
| Little, JR | 1 |
| Meese, RB | 1 |
3 reviews available for labetalol and Brain Vascular Disorders
| Article | Year |
|---|---|
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
[Treatment of medical complications: hypertension/hypotension, hyperglycemia, hyperthermia, hypoxia, cardiac complications and pulmonary embolism].
Topics: Administration, Oral; Antihypertensive Agents; Arrhythmias, Cardiac; Cerebrovascular Disorders; Hear | 1995 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
1 trial available for labetalol and Brain Vascular Disorders
| Article | Year |
|---|---|
Labetalol: response and safety in critically ill hemorrhagic stroke patients.
Topics: Adult; Aged; Blood Pressure; Cerebral Hemorrhage; Cerebrovascular Disorders; Critical Illness; Femal | 1993 |
2 other studies available for labetalol and Brain Vascular Disorders
| Article | Year |
|---|---|
Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Brain; Cerebrovascular Disorders; Disease Susc | 1991 |
The safety of cumulative doses of labetalol in perioperative hypertension.
Topics: Adult; Cerebrovascular Disorders; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Infusions, | 1989 |